Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists
Saved in:
| Main Author: | |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Hoboken, N.J.
J. Wiley
©2005
|
| Series: | Methods of biochemical analysis
v. 46 |
| Subjects: | |
| Online Access: | FAW01 FAW02 Volltext |
| Item Description: | Includes bibliographical references and index Why enzymes as drug targets? -- Enzyme reaction mechanisms. -- Reversible modes of inhibitor interactions with enzymes. -- Assay considerations for compound library screening. -- Lead organization and structure-activity relationships for reversible inhibitors. -- Slow binding inhibitors. -- Tight binding inhibitors. -- Irreversible enzyme inactivators. -- Appendix 1. Kinetics if biochemical reactions. -- Appendix 2. Derivation of the enzyme-ligand binding isotherm equation. -- Appendix 3. Serial dilution schemes Most enzymology textbooks, including his own, address biochemists and other researchers, says Copeland, a researcher in enzymology and mechanistic pharmacology at a large pharmaceutical corporation. Here he provides chemists and pharmacologists with key information to answer such questions as what opportunities for inhibitor interactions with enzym |
| Physical Description: | 1 Online-Ressource (xvii, 271 pages) |
| ISBN: | 0471723266 9780471723264 |
Staff View
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV043080814 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151126s2005 |||| o||u| ||||||eng d | ||
| 020 | |a 0471723266 |c electronic bk. |9 0-471-72326-6 | ||
| 020 | |a 9780471723264 |c electronic bk. |9 978-0-471-72326-4 | ||
| 035 | |a (OCoLC)58964965 | ||
| 035 | |a (DE-599)BVBBV043080814 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 615/.19 |2 22 | |
| 084 | |a VS 5350 |0 (DE-625)147687:253 |2 rvk | ||
| 100 | 1 | |a Copeland, Robert Allen |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Evaluation of enzyme inhibitors in drug discovery |b a guide for medicinal chemists and pharmacologists |c Robert A. Copeland |
| 264 | 1 | |a Hoboken, N.J. |b J. Wiley |c ©2005 | |
| 300 | |a 1 Online-Ressource (xvii, 271 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Methods of biochemical analysis |v v. 46 | |
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a Why enzymes as drug targets? -- Enzyme reaction mechanisms. -- Reversible modes of inhibitor interactions with enzymes. -- Assay considerations for compound library screening. -- Lead organization and structure-activity relationships for reversible inhibitors. -- Slow binding inhibitors. -- Tight binding inhibitors. -- Irreversible enzyme inactivators. -- Appendix 1. Kinetics if biochemical reactions. -- Appendix 2. Derivation of the enzyme-ligand binding isotherm equation. -- Appendix 3. Serial dilution schemes | ||
| 500 | |a Most enzymology textbooks, including his own, address biochemists and other researchers, says Copeland, a researcher in enzymology and mechanistic pharmacology at a large pharmaceutical corporation. Here he provides chemists and pharmacologists with key information to answer such questions as what opportunities for inhibitor interactions with enzym | ||
| 650 | 7 | |a MEDICAL / Drug Guides |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacy |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Nursing / Pharmacology |2 bisacsh | |
| 650 | 4 | |a Antienzymes / Emploi en thérapeutique / Tests | |
| 650 | 4 | |a Médicaments / Conception | |
| 650 | 4 | |a Antienzymes / Relations structure-activité | |
| 650 | 7 | |a Enzyminhibitoren |2 gtt | |
| 650 | 4 | |a Enzyme Inhibitors / therapeutic use | |
| 650 | 4 | |a Drug Design | |
| 650 | 4 | |a Enzyme Inhibitors / chemistry | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Enzyme inhibitors |x Therapeutic use |x Testing | |
| 650 | 4 | |a Drugs |x Design | |
| 650 | 4 | |a Enzyme inhibitors |x Structure-activity relationships | |
| 650 | 0 | 7 | |a Enzyminhibitor |0 (DE-588)4152479-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Enzyminhibitor |0 (DE-588)4152479-2 |D s |
| 689 | 0 | 1 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 0-471-68696-4 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 978-0-471-68696-5 |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=129367 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028505006 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=129367 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=129367 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Record in the Search Index
| _version_ | 1804175472869769216 |
|---|---|
| any_adam_object | |
| author | Copeland, Robert Allen |
| author_facet | Copeland, Robert Allen |
| author_role | aut |
| author_sort | Copeland, Robert Allen |
| author_variant | r a c ra rac |
| building | Verbundindex |
| bvnumber | BV043080814 |
| classification_rvk | VS 5350 |
| collection | ZDB-4-EBA |
| ctrlnum | (OCoLC)58964965 (DE-599)BVBBV043080814 |
| dewey-full | 615/.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.19 |
| dewey-search | 615/.19 |
| dewey-sort | 3615 219 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03696nmm a2200661zcb4500</leader><controlfield tag="001">BV043080814</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151126s2005 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0471723266</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-471-72326-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780471723264</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-471-72326-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)58964965</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043080814</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.19</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 5350</subfield><subfield code="0">(DE-625)147687:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Copeland, Robert Allen</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluation of enzyme inhibitors in drug discovery</subfield><subfield code="b">a guide for medicinal chemists and pharmacologists</subfield><subfield code="c">Robert A. Copeland</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hoboken, N.J.</subfield><subfield code="b">J. Wiley</subfield><subfield code="c">©2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xvii, 271 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Methods of biochemical analysis</subfield><subfield code="v">v. 46</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Why enzymes as drug targets? -- Enzyme reaction mechanisms. -- Reversible modes of inhibitor interactions with enzymes. -- Assay considerations for compound library screening. -- Lead organization and structure-activity relationships for reversible inhibitors. -- Slow binding inhibitors. -- Tight binding inhibitors. -- Irreversible enzyme inactivators. -- Appendix 1. Kinetics if biochemical reactions. -- Appendix 2. Derivation of the enzyme-ligand binding isotherm equation. -- Appendix 3. Serial dilution schemes</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Most enzymology textbooks, including his own, address biochemists and other researchers, says Copeland, a researcher in enzymology and mechanistic pharmacology at a large pharmaceutical corporation. Here he provides chemists and pharmacologists with key information to answer such questions as what opportunities for inhibitor interactions with enzym</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Drug Guides</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacy</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Nursing / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antienzymes / Emploi en thérapeutique / Tests</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Médicaments / Conception</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antienzymes / Relations structure-activité</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Enzyminhibitoren</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Enzyme Inhibitors / therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Enzyme Inhibitors / chemistry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Enzyme inhibitors</subfield><subfield code="x">Therapeutic use</subfield><subfield code="x">Testing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Enzyme inhibitors</subfield><subfield code="x">Structure-activity relationships</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Enzyminhibitor</subfield><subfield code="0">(DE-588)4152479-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Enzyminhibitor</subfield><subfield code="0">(DE-588)4152479-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">0-471-68696-4</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">978-0-471-68696-5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=129367</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028505006</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=129367</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=129367</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043080814 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:16:50Z |
| institution | BVB |
| isbn | 0471723266 9780471723264 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028505006 |
| oclc_num | 58964965 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 Online-Ressource (xvii, 271 pages) |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2005 |
| publishDateSearch | 2005 |
| publishDateSort | 2005 |
| publisher | J. Wiley |
| record_format | marc |
| series2 | Methods of biochemical analysis |
| spelling | Copeland, Robert Allen Verfasser aut Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists Robert A. Copeland Hoboken, N.J. J. Wiley ©2005 1 Online-Ressource (xvii, 271 pages) txt rdacontent c rdamedia cr rdacarrier Methods of biochemical analysis v. 46 Includes bibliographical references and index Why enzymes as drug targets? -- Enzyme reaction mechanisms. -- Reversible modes of inhibitor interactions with enzymes. -- Assay considerations for compound library screening. -- Lead organization and structure-activity relationships for reversible inhibitors. -- Slow binding inhibitors. -- Tight binding inhibitors. -- Irreversible enzyme inactivators. -- Appendix 1. Kinetics if biochemical reactions. -- Appendix 2. Derivation of the enzyme-ligand binding isotherm equation. -- Appendix 3. Serial dilution schemes Most enzymology textbooks, including his own, address biochemists and other researchers, says Copeland, a researcher in enzymology and mechanistic pharmacology at a large pharmaceutical corporation. Here he provides chemists and pharmacologists with key information to answer such questions as what opportunities for inhibitor interactions with enzym MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Antienzymes / Emploi en thérapeutique / Tests Médicaments / Conception Antienzymes / Relations structure-activité Enzyminhibitoren gtt Enzyme Inhibitors / therapeutic use Drug Design Enzyme Inhibitors / chemistry Medizin Enzyme inhibitors Therapeutic use Testing Drugs Design Enzyme inhibitors Structure-activity relationships Enzyminhibitor (DE-588)4152479-2 gnd rswk-swf Arzneimittelentwicklung (DE-588)4143176-5 gnd rswk-swf Enzyminhibitor (DE-588)4152479-2 s Arzneimittelentwicklung (DE-588)4143176-5 s 1\p DE-604 Erscheint auch als Druck-Ausgabe, Hardcover 0-471-68696-4 Erscheint auch als Druck-Ausgabe, Hardcover 978-0-471-68696-5 http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=129367 Aggregator Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Copeland, Robert Allen Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Antienzymes / Emploi en thérapeutique / Tests Médicaments / Conception Antienzymes / Relations structure-activité Enzyminhibitoren gtt Enzyme Inhibitors / therapeutic use Drug Design Enzyme Inhibitors / chemistry Medizin Enzyme inhibitors Therapeutic use Testing Drugs Design Enzyme inhibitors Structure-activity relationships Enzyminhibitor (DE-588)4152479-2 gnd Arzneimittelentwicklung (DE-588)4143176-5 gnd |
| subject_GND | (DE-588)4152479-2 (DE-588)4143176-5 |
| title | Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists |
| title_auth | Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists |
| title_exact_search | Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists |
| title_full | Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists Robert A. Copeland |
| title_fullStr | Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists Robert A. Copeland |
| title_full_unstemmed | Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists Robert A. Copeland |
| title_short | Evaluation of enzyme inhibitors in drug discovery |
| title_sort | evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists |
| title_sub | a guide for medicinal chemists and pharmacologists |
| topic | MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Antienzymes / Emploi en thérapeutique / Tests Médicaments / Conception Antienzymes / Relations structure-activité Enzyminhibitoren gtt Enzyme Inhibitors / therapeutic use Drug Design Enzyme Inhibitors / chemistry Medizin Enzyme inhibitors Therapeutic use Testing Drugs Design Enzyme inhibitors Structure-activity relationships Enzyminhibitor (DE-588)4152479-2 gnd Arzneimittelentwicklung (DE-588)4143176-5 gnd |
| topic_facet | MEDICAL / Drug Guides MEDICAL / Pharmacology MEDICAL / Pharmacy MEDICAL / Nursing / Pharmacology Antienzymes / Emploi en thérapeutique / Tests Médicaments / Conception Antienzymes / Relations structure-activité Enzyminhibitoren Enzyme Inhibitors / therapeutic use Drug Design Enzyme Inhibitors / chemistry Medizin Enzyme inhibitors Therapeutic use Testing Drugs Design Enzyme inhibitors Structure-activity relationships Enzyminhibitor Arzneimittelentwicklung |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=129367 |
| work_keys_str_mv | AT copelandrobertallen evaluationofenzymeinhibitorsindrugdiscoveryaguideformedicinalchemistsandpharmacologists |